Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients

Alfred Zippelius, Asma Gati, Tammo Bartnick, Senta Walton, Bernhard Odermatt, Elke Jaeger, Reinhold Dummer, Mirjana Urosevic, Valeriy Filonenko, Kazuhiro Osanai, Holger Moch, Yao-Tseng Chen, Lloyd J Old, Alexander Knuth, Dirk Jaeger

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Expression pattern and immunogenicity are critical issues that define tumor antigens as diagnostic markers and potential targets for immunotherapy. The development of SEREX (serological analysis of recombinant expression libraries) has provided substantial progress in the identification of tumor antigens eliciting both cellular and humoral immune responses in cancer patients. By SEREX, we have previously identified RAB38/NY-MEL-1 as a melanocyte differentiation antigen that is highly expressed in normal melanocytes and melanoma tissues but not in other normal tissues or cancer types. In this study, we further demonstrate that RAB38/NY-MEL-1 is strongly immunogenic, leading to spontaneous antibody responses in a significant proportion of melanoma patients. The immune response occurs solely in malignant melanoma patients and was not detected in patients with other diseases, such as vitiligo, affecting melanocytes. Fine analysis of the spontaneous anti-RAB38/NY-MEL-1 antibody response reveals a polyclonal B cell recognition targeting various epitopes, although a dominant immunogenic region was preferentially recognized. Interestingly, our data indicate that this recognition is not rigid in the course of a patient's response, as the dominant epitope changes during the disease evolution. Implications for the understanding of spontaneous humoral immune responses are discussed.

Original languageEnglish
Pages (from-to)249-58
Number of pages10
JournalCancer immunology, immunotherapy
Issue number2
Publication statusPublished - Feb 2007
Externally publishedYes


Dive into the research topics of 'Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients'. Together they form a unique fingerprint.

Cite this